June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Newly Diagnosed Central Serous Chorioretinopathy: Demographics and Epidemiology from the IRIS® Registry (Intelligent Research in Sight)
Author Affiliations & Notes
  • Kapil Mishra
    Byers Eye Institute, Stanford University School of Medicine, Stanford, California, United States
    Byers Eye Institute, Stanford University, Spencer Center for Vision Research, California, United States
  • Arthur Brant
    Byers Eye Institute, Stanford University School of Medicine, Stanford, California, United States
    Byers Eye Institute, Stanford University, Spencer Center for Vision Research, California, United States
  • Suzann Pershing
    Byers Eye Institute, Stanford University School of Medicine, Stanford, California, United States
    VA Palo Alto Health Care System, Palo Alto, California, United States
  • Ashton Tristan Perlroth
    Byers Eye Institute, Stanford University School of Medicine, Stanford, California, United States
    Byers Eye Institute, Stanford University, Spencer Center for Vision Research, California, United States
  • Henry Bair
    Byers Eye Institute, Stanford University School of Medicine, Stanford, California, United States
    Byers Eye Institute, Stanford University, Spencer Center for Vision Research, California, United States
  • Christine Xu
    Byers Eye Institute, Stanford University School of Medicine, Stanford, California, United States
    Byers Eye Institute, Stanford University, Spencer Center for Vision Research, California, United States
  • Diana V Do
    Byers Eye Institute, Stanford University School of Medicine, Stanford, California, United States
    Byers Eye Institute, Stanford University, Spencer Center for Vision Research, California, United States
  • Footnotes
    Commercial Relationships   Kapil Mishra None; Arthur Brant None; Suzann Pershing Research to Prevent Blindness, NEI P30EY026877, Code F (Financial Support); Ashton Perlroth None; Henry Bair None; Christine Xu None; Diana Do Allergan, Code C (Consultant/Contractor), Kodiak Sciences, Code C (Consultant/Contractor), Novartis, Code C (Consultant/Contractor), Regeneron, Code C (Consultant/Contractor), Steve Zelencik Retina Research Fund, Code F (Financial Support), Gregory Wallace Retina Research Fund, Code F (Financial Support), Boeringer Ingelheim, Code F (Financial Support)
  • Footnotes
    Support  NEI P30EY026877 and Research to Prevent Blindness, Inc
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2541 – A0110. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kapil Mishra, Arthur Brant, Suzann Pershing, Ashton Tristan Perlroth, Henry Bair, Christine Xu, Diana V Do; Newly Diagnosed Central Serous Chorioretinopathy: Demographics and Epidemiology from the IRIS® Registry (Intelligent Research in Sight). Invest. Ophthalmol. Vis. Sci. 2022;63(7):2541 – A0110.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine demographics and visual acuity for patients with newly diagnosed central serous chorioretinopathy (CSCR) as captured in the IRIS Registry.

Methods : We identified patients with a new diagnosis of CSCR between 2017 and 2018 in the IRIS Registry. We investigated patient characteristics (age, sex, and race/ethnicity) associated with CSCR, and visual acuity (VA) at time of first diagnosis and routine follow-up visits. We processed multivariate regressions to analyze the odds of developing CSCR relative to all patients in the IRIS Registry database.

Results : 28,323 patients were newly diagnosed with CSCR between 2017 and 2018 in the IRIS Registry. The majority of patients with new CSCR were male (68.54%), and the decade with the most CSCR diagnoses was 51-60 years (23.68%). Mean VA at time of diagnosis was 0.29 logMAR (about 20/40) which decreased only slightly to 0.33 logMAR 1 year following diagnosis. Compared to patients in the IRIS Registry without CSCR, patients with CSCR were more likely to be of Asian (Odds ratio (OR) 1.65, p < 0.001) or Hispanic descent (OR 1.5, p < 0.001) using White as a reference, and were more likely to have Commercial (OR 1.12, p <0.001) or Military (OR 1.29, p <0.001) insurance compared to Medicare, Medicaid (using no insurance as a reference).

Conclusions : According to the IRIS Registry, patients with newly diagnosed CSCR were most commonly middle-aged male, of Asian or Hispanic descent, and with commercial or military insurance. Initial VA at diagnosis was 20/40, and this was relatively stable 1 year following diagnosis.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×